Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

GTC to go private for $18M

November 8, 2010 4:36 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Framingham biotechnology firm GTC Biotherapeutics Inc. has agreed to be taken private by French strategic partner LFB Biotechnologies for about $18.3 million. LFB first made its offer last month for $17 million.

Medtronic, Stryker, and BrainLAB Covered in New Surgical Navigation Market Research Reports Released by Millennium Research Group

November 8, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

TORONTO, Nov. 8, 2010 /- Millennium Research Group (MRG), the global authority on medical technology market intelligence, has released its latest surgical navigation systems research data on both the US and European geographies. These two reports cover the breakdown of the surgical...

TOPICS:

Voxiva Inc. and PositiveID Corporation Announce a Partnership to Offer an Integrated Mobile Diabetes Solution Combining Mobile Glucometer Technology with a Mobile-Based Diabet...

November 8, 2010 4:33 am | by PositiveID | News | Comments

Voxiva Inc. and PositiveID Corporation Announce a Partnership to Offer an Integrated Mobile Diabetes Solution Combining Mobile Glucometer Technology with a Mobile-Based Diabetes Management Program

TOPICS:
Advertisement

Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years

November 8, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

REDWOOD CITY, Calif., Nov. 8, 2010 /- Arstasis is pleased to announce that patient enrollment has begun in the RECITAL (A Patient Registry Evaluating Closure Following Access with the Arstasis One Access System) Study.  The non-randomized, prospective, post-approval study is...

TOPICS:

Biotel, Inc. Announces Definitive Merger Agreement With CardioNet, Inc.

November 8, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

EAGAN, Minn., Nov. 8, 2010 /- CardioNet, Inc. (Nasdaq: BEAT ), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced today that the Company entered into a definitive merger agreement with Biotel, Inc. (OTC...

TOPICS:

Post-menopausal women over 40 needed for dry eye study

November 8, 2010 3:35 am | by Baylor College of Medicine | News | Comments

Women over the age of 40 who are past menopause can take part in a research study evaluating omega-3 fatty acids or fish oil as a treatment for dry eye. Dry eye is one of the most prevalent eye conditions in the United States, said Dr. Stephen Pflugfelder , professor of ophthalmology at...

TOPICS:

Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2011 Financial Results

November 8, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

BETHESDA, Md., Nov. 8, 2010 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX ), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the second quarter and first half of...

TOPICS:

Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government

November 8, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

LONGMONT, Colo., Nov. 8, 2010 /- Parascript, LLC, the image analysis and pattern recognition technology provider, today announced that it was awarded a cash grant of $244,479.25 under the U.S. Government's Affordable Care Act. Under this act, the therapeutic discovery project program...

TOPICS:
Advertisement

Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting

November 8, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

DANBURY, Conn., Nov. 8, 2010 /-  Biodel Inc. (Nasdaq: BIOD ) announced today that the following abstracts describing recent findings from the company's product development programs have been accepted for poster presentation at the Tenth Annual Diabetes Technology Meeting in Bethesda,...

TOPICS:

TTI: The Big Job-"Robotti Campaign Speech"

November 8, 2010 3:32 am | by ttithebigjob | Videos | Comments

http://www.ttiinc.com/thebigjob

Need Help Affording Your Meds? LegitScript Adds Patient Assistance Feature

November 7, 2010 10:32 pm | by Bio-Medicine.Org | News | Comments

PORTLAND, Oregon, Nov. 8, 2010 /- A leading Internet pharmacy verification service offers a new message for patients: There are ways to get affordable medicines without using unregulated, potentially dangerous "rogue" Internet pharmacies. LegitScript, a firm that monitors "rogue" Internet...

TOPICS:

WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility

November 7, 2010 10:32 pm | by Bio-Medicine.Org | News | Comments

SHANGHAI, Nov. 8, 2010 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good...

TOPICS:

Combating Childhood Cancer

November 7, 2010 10:31 pm | by San Diego Business Journal | News | Comments

Beth Anne Baber believes the intellectual capital, business acumen and philanthropic potential in San Diego provide the ideal environment to support the growth of a new institute that focuses on pediatric cancer research, diagnosis and treatment.

TOPICS:

Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent

November 7, 2010 8:35 pm | by Bio-Medicine.Org | News | Comments

RESEARCH TRIANGLE PARK, N.C., Nov. 7, 2010 /- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today reaffirmed its commitment to the dual development of CMX001 as a medical countermeasure against smallpox and as a broad-spectrum antiviral...

TOPICS:

Harvard's headache cure: LSD?

November 7, 2010 8:34 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

Move over, Advil. Harvard Medical School researcher John Halpern says LSD, the hallucinogen at the heart of the 1960s drug counterculture, holds a better treatment for cluster headaches, and he's formed a company he hopes will bring to market a drug based on his research.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading